Involuntary movements caused by tardive dyskinesia (TD), a movement disorder induced by dopamine-receptor antagonists like ...

Teva Pharmaceuticals has a new game plan for raising awareness of tardive dyskinesia (TD). | Teva Pharmaceuticals has a new ...

This football season, Teva is increasing education around tardive dyskinesia (TD) by launching ‘The Other TD’ campaignTD is a ...

Many people like to snack on peanut butter with apple slices for the vitamin E, but you have to be careful of other ...

In a new cohort of 27 adults from the IMPACT-TD Registry, up to 77% of participants reported improvements in aspects of their ...

This football season, Teva is increasing education around tardive dyskinesia (TD) by launching 'The Other TD' campaignTD is a chronic movement disorder impacting one in four people who take certain pr ...

QOL Medical to Acquire All Outstanding Shares of Evoke for $11.00 Per Share in Cash Represents a 139.7% premium to most recent Nasdaq closing price Transaction expected to close by the end of 2025 ...

Neurocrine Biosciences has penned a deal with China’s TransThera Sciences potentially worth more than $880 million in biobucks for inhibitors aimed at a red-hot inflammation target. | Neurocrine ...

Pharmaceuticals announced the launch of ‘The Other TD,’ a disease education campaign leveraging the broad recognition of football ...

Christoph U. Correll, MD, professor of psychiatry at The Zucker School of Medicine at Hofstra/Northwell and professor and chair of the department of child and adolescent psychiatry at Charité ...

In Q3, $687 million of its Neurocrine’s income came from sales of Ingrezza, its treatment for the movement disorder tardive dyskinesia, as well as chorea ... significantly easing symptoms of major ...